Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 1/2012

01-02-2012 | Nonstatin Drugs (W Borden, Section Editor)

Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus

Authors: Leon I. Igel, Amanda G. Powell, Caroline M. Apovian, Louis J. Aronne

Published in: Current Atherosclerosis Reports | Issue 1/2012

Login to get access

Abstract

Overweight and obesity are now recognized as leading causes of diseases such as type 2 diabetes, hypertension, hyperlipidemia, and ultimately, cardiovascular disease. Despite the serious consequences, roughly two thirds of Americans are presently classified as overweight, and about one third are classified as obese. Weight loss via lifestyle modification and pharmacotherapy can promote improvement in many of these obesity-related conditions. This review addresses recent advances in pharmacotherapy for the management of obesity and obesity-related co-morbidities, with a focus on the management of obesity specifically in individuals with type 2 diabetes. Emphasis is also placed on a proposed paradigm shift from the glucose-centric to the weight-centric management of type 2 diabetes mellitus.
Literature
1.
2.
• Flegal KM, Carroll MD, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41. The authors examined trends in obesity from 1999 through 2008 and also assessed the prevalence of obesity and overweight for 2007–2008. The authors found a very high prevalence of obesity in the US (32.2% among adult men and 35.5% among adult women). PubMedCrossRef
3.
4.
5.
Aronne LJ. A practical guide to drug-induced weight gain. Minneapolis: McGraw-Hill; 2002. p. 77–91.
6.
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59. The authors examined whether intensive glucose lowering therapy targeting normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. The authors found that intensive glucose lowering therapy actually increased mortality and did not significantly reduce major cardiovascular events in this high-risk population. PubMedCrossRef
7.
Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9:326S–34S.PubMedCrossRef
8.
NHLBI Obesity Education Initiative Working Group: The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. NIH/NHLBI/NAASO; October 2000. NIH Publication 00 -4084
9.
Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152(6):346–57.PubMed
10.
Koska J, Ortega E, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia, Springer Berlin/Heidelberg. 2009;52:385–93.
11.
Over-the-counter weight loss with orlistat? Drug Ther Bull. 2009;47(11):125–127.
12.
Torgerson JS, Hauptman J, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27(1):155–61.PubMedCrossRef
13.
14.
Hauptman J, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–7.PubMedCrossRef
15.
Rössner S, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8:49–61.PubMedCrossRef
16.
17.
Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRef
18.
DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. NEJM. 1995;333(9):541–9.PubMedCrossRef
19.
Robinson AC, Burke J, et al. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 1998;21(5):701–5.PubMedCrossRef
20.
Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1–14.PubMedCrossRef
21.
• The Look AHEAD Research Group (2010). Long term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: four year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566–75. The authors examined the effects of intensive lifestyle intervention as compared to a control condition of diabetes support and education on changes in weight, fitness, and cardiovascular disease risk factors in 5145 overweight or obese subjects with type 2 diabetes over 4 years. They found that intensive lifestyle intervention produced sustainable weight loss as well as improvements in fitness, glycemic control, and cardiovascular disease risk factors. CrossRef
22.
23.
Moretto T, Milton D, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–60.PubMedCrossRef
24.
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus. Diabetes Care. 2005;28:1092–100.PubMedCrossRef
25.
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–35.PubMedCrossRef
26.
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.PubMedCrossRef
27.
Blonde L, Klein EJ, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436–47.PubMedCrossRef
28.
Buse JB, Klonoff DC, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo controlled trials. Clin Ther. 2007;29:139–53.PubMedCrossRef
29.
Horton ES, Silberman C, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33(8):1759–65.PubMedCrossRef
30.
31.
32.
Russell-Jones D, et al. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297(1–2):137–40.PubMedCrossRef
33.
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81. The authors investigated the safety and efficacy of liraglutide as monotherapy as compared to glimepiride monotherapy in 746 subjects with type 2 diabetes over 52 weeks. They found that liraglutide was effective in the treatment of type 2 diabetes mellitus and led to greater reductions in HbA1c, weight, and blood pressure than did glimepiride without the risk of hypoglycemia. PubMedCrossRef
34.
Nauck MA, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care. 2009;32:84–90.PubMedCrossRef
35.
Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. J Clin Endocrinol Metab. 2011;96:1301–10. Epub 2011 Feb 9. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.PubMedCrossRef
36.
37.
Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year randomized controlled trial. Diabet Med. 2004;11:1204–12.CrossRef
38.
Younk LM, Mikeladze M, et al. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12(9):1439–51.PubMedCrossRef
39.
Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;3:784–90.CrossRef
40.
Aronne L, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92(8):2977–83.PubMedCrossRef
41.
Aronne LJ, Isoldi KK, Roarke DT. The Johns Hopkins University textbook of dyslipidemia chapter 24: therapeutic options for modifying obesity and cardiometabolic risk factors. Kwiterovich PO, editor. Lippincott, Williams and Wilkins; 2009. pp. 277–91.
42.
Smith SR, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816–23.PubMedCrossRef
43.
Ravussin E, Smith SR, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009;17(9):1736–43.PubMedCrossRef
44.
45.
46.
Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin N Am. 2005;39(1):69–79.CrossRef
47.
Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26:262–73.PubMedCrossRef
48.
Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–46.PubMed
49.
50.
Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011 Apr 28. [Epub ahead of print].
51.
• Gadde KM, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52. The authors assessed the efficacy and safety of phentermine plus topiramate controlled-release combination in 2487 individuals who were overweight and obese with two or more risk factors. They found that phentermine plus topiramate produced significant weight loss as well as improvement in many metabolic risk factors over the 56 weeks of the trial. PubMedCrossRef
52.
• Greenway FL, Fujioka K, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605. The authors assessed the effect of sustained-release naltrexone and bupropion on bodyweight in 1742 overweight and obese subjects and found that the combination promoted significant weight loss as well as improvements in many metabolic risk factors. PubMedCrossRef
53.
• Smith SR, Weissman NJ, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56. The authors evaluated the use lorcaserin as compared to placebo in 3182 overweight and obese adults over 52 weeks. They found that lorcaserin promoted significant weight loss as well as improvements in many metabolic risk factors. PubMedCrossRef
54.
Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323–30.PubMedCrossRef
55.
• Bailey CJ, Gross JL, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223–33. The authors evaluated the adjunct use of dapagliflozin in 546 individuals with type 2 diabetes treated with metformin over 24 weeks. They found that dapagliflozin promoted significant weight loss as well as improved glycemic and blood pressure control. PubMedCrossRef
56.
Musso G, Gambino R, et al. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2011; Apr 15. [Epub ahead of print]1-19.
57.
Siram AT, Yanagisawa R, Skamagas M. Weight management in type 2 diabetes mellitus. Mount Sinai J Med. 2010;77:533–48.CrossRef
Metadata
Title
Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus
Authors
Leon I. Igel
Amanda G. Powell
Caroline M. Apovian
Louis J. Aronne
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 1/2012
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0221-0

Other articles of this Issue 1/2012

Current Atherosclerosis Reports 1/2012 Go to the issue

Statin Drugs (M Clearfield, Section Editor)

A Review of the Rationale for Additional Therapeutic Interventions to Attain Lower LDL-C When Statin Therapy Is Not Enough

Nonstatin Drugs (W Borden, Section Editor)

Novel Antiplatelet Therapies

Statin Drugs (M Clearfield, Section Editor)

Role of C-Reactive Protein When Prescribing a Statin

Statin Drugs (M Clearfield, Section Editor)

Initiation of Statin Therapy: Are There Age Limits?

Nonstatin Drugs (W Borden, Section Editor)

New Horizons for Cholesterol Ester Transfer Protein Inhibitors

Nonstatin Drugs (W Borden, Section Editor)

Lipid Effects of Antihypertensive Medications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits